Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and S-1 Maintenance in HER2-Negative Advanced Gastric Cancer
NCT05170542Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 42 months. Started Dec 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05170542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170542.